Accrol Group Holdings Report Strong Performance with Margins and Volume Continuing to Grow

Accrol Group Holdings plc
[shareaholic app="share_buttons" id_name="post_below_content"]

Accrol Group Holdings Plc (LON:ACRL), the UK’s leading independent tissue converter, has announced the following trading update ahead of its Half Year Results for the six months ended 31 October 2023, which are scheduled to be released in late January 2024.

The Board is pleased to report that the Group performed strongly in H1 FY24:

·     Volume growth continued throughout the Period;

·     Margins returned to pre-pandemic levels, quicker than forecast, with the Board now expecting Adjusted EBITDA1 for FY24 of at least £21m;

·     Adjusted net debt2 at 31 October 2023 was £25.5m (H1 FY23 £30.5m), as a result of strong cash generation, driven by the operational efficiencies of the business. The Board now anticipates that adjusted net debt will be close to 1x EBITDA by the full year end.

The Group continues to demonstrate its strong market position, building on its strong customer base and market-leading products, and is well positioned to deliver further growth.

Gareth Jenkins, Chief Executive Officer of Accrol, said:

“We are clearly very pleased with this performance. We continue to deliver by having great quality and value products which meet every consumer’s budget. Our strong relationship with the retailers and our robust supply model are ensuring we can continue to deliver a strong set of results in a changing market environment.”

1Adjusted EBITDA is defined as profit before finance costs, tax, depreciation, amortisation, separately disclosed items and share based payments
2Adjusted net debt excludes operating type leases recognised on the balance sheet in accordance with IFRS 16

Market expectations as at 21 November 2023 for FY24 (Shore Capital & Zeus): revenue of £205m, adjusted EBITDA of £20.5m, adjusted profit before tax of £10.8m and net debt of £20.1m.

Accrol Group Holdings plc is a leading tissue converter and supplier of toilet tissues, kitchen rolls, facial tissues, and wet wipes to many of the UK’s leading discounters and grocery retailers across the UK. The Group now operates from five manufacturing sites suppling the UK tissue wet wipes market valued at c£2.7bn at retail sales value.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
Accrol Group Holdings plc (LON:ACRL) has announced the publication of a shareholder circular detailing terms of the Scheme. Learn more here.
Discover the latest results and overview of Accrol Group Holdings, the UK's top independent tissue converter, led by CEO Gareth Jenkins and CFO Chris Welsh.
In this interview, Gervais Williams, co-fund manager of Miton UK MicroCap Trust, discusses navigating the economic landscape and standout companies in 2024. Find out more here. #investment #microcap
Accrol Group Holdings plc has reported strong H1 FY24 results, with impressive growth in adjusted EBITDA and adjusted PBT. The company remains on track to meet expectations and has seen gains in market share. Furthermore, the private label segment of the UK tissue market continues to increase, and the sales of biodegradable wet wipes have been exceptionally strong. Accrol's outlook remains positive with expected further volume growth.
Accrol Group Holdings plc has reported strong performance in H1 FY24, with branded volumes rising by 45% and margins returning to pre-pandemic levels. The group is on track to deliver FY24 results in line with expectations and expects to outperform previous expectations for FY25.

Search

Search